Recurrent Adult Soft Tissue Sarcoma: Clinical Trials

47 trials for Recurrent Adult Soft Tissue Sarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

35 completed, 7 terminated, 4 withdrawn, 1 recruiting. 32 Phase 2, 12 Phase 1, 4 Not applicable, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 232Completed 26, Terminated 5, Withdrawn 1
Phase 112Completed 9, Terminated 2, Withdrawn 1
Not applicable4Completed 1, Recruiting 1, Terminated 1, Withdrawn 1
Early Phase 11Withdrawn 1

Follow Recurrent Adult Soft Tissue Sarcoma: new trials by email Literature Review of Recurrent Adult Soft Tissue Sarcoma trials Research Report on Recurrent Adult Soft Tissue Sarcoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
SMMART Adaptive Clinical Treatment (ACT) Trial
Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm
Early Phase 1WithdrawnOHSU Knight Cancer Institute2023-01-302024-01-23
Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma
Durvalumab and Tremelimumab, Doxorubicin - Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma
Phase 2CompletedAIO-Studien-gGmbH1032017-12-152023-06-15
Combination of Cryosurgery and NK Immunotherapy for Recurrent Sarcoma
Cryosurgery, NK immunotherapy - Recurrent Adult Soft Tissue Sarcoma
Phase 1 / Phase 2CompletedFuda Cancer Hospital, Guangzhou302016-07-012019-09-12
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
Conventional Surgery, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis - Recurrent Adult Soft Tissue Sarcoma
Not applicableRecruitingJonsson Comprehensive Cancer Center512016-02-032026-03-10
Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)
CMB305, atezolizumab - Sarcoma, Myxoid/Round Cell Liposarcoma
Phase 2TerminatedImmune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)892015-04-292020-07-07
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Pazopanib Hydrochloride, Oral Topotecan Hydrochloride, Laboratory Biomarker Analysis - Adult Liposarcoma, Metastatic Liposarcoma
Phase 2CompletedNorthwestern University1782015-03-212022-06-07
NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cyclophosphamide, Laboratory Biomarker Analysis - Adult Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
Phase 1WithdrawnFred Hutchinson Cancer Center2014-07-012016-02-03
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
regorafenib - Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma
Phase 2CompletedNorthwestern University312014-06-132022-04-25
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
tivozanib, laboratory biomarker analysis - Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma
Phase 2CompletedNorthwestern University582013-03-062019-09-09
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
Bevacizumab, Cetuximab, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Castleman Disease
Phase 1TerminatedM.D. Anderson Cancer Center1162012-10-162026-11-05
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Alisertib, Laboratory Biomarker Analysis - Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma
Phase 2CompletedNational Cancer Institute (NCI)722012-08-222017-11-30
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Pharmacological Study, Romidepsin - Glioma, Hematopoietic and Lymphoid Cell Neoplasm
Phase 1CompletedNational Cancer Institute (NCI)372012-08-032025-02-07
Biomarkers in Patients With Advanced Rhabdomyosarcoma
Laboratory Biomarker Analysis - Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma
CompletedChildren's Oncology Group102012-08-012016-05-18
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
Laboratory Biomarker Analysis, Trebananib - Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma
Phase 2CompletedNational Cancer Institute (NCI)162012-07-012015-10-19
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
isolated limb perfusion, melphalan, quality-of-life assessment - Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin
Not applicableWithdrawnAlbert Einstein College of Medicine2012-04-012015-07-23
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Phase 2CompletedOHSU Knight Cancer Institute542012-03-132021-09-27
Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery
cyclophosphamide, NY-ESO-1-specific T cells, laboratory biomarker analysis - Adult Liposarcoma, Adult Synovial Sarcoma
Phase 1CompletedFred Hutchinson Cancer Center62012-01-012014-12-11
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
pazopanib hydrochloride, laboratory biomarker analysis, positron emission tomography - Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma
Phase 2CompletedFox Chase Cancer Center292011-11-032022-08-19
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
intensity-modulated radiation therapy - Adult Rhabdomyosarcoma, Lung Metastases
Not applicableCompletedAnn & Robert H Lurie Children's Hospital of Chicago202011-02-012025-02-10
Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
diagnostic laboratory biomarker analysis, everolimus, imatinib mesylate - Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)142011-01-012014-10-08

Showing 20 of 47. Sign in to see all of them.

Narrower conditions

Sarcoma (47)  ·  Rhabdomyosarcoma (12)  ·  Sarcoma, Synovial (11)  ·  Liposarcoma (10)  ·  Hemangiosarcoma (8)  ·  Osteosarcoma (8)  ·  Histiocytoma, Malignant Fibrous (7)  ·  Leiomyosarcoma (7)  ·  Fibrosarcoma (6)  ·  Neuroectodermal Tumors, Primitive, Peripheral (6)  ·  Neurofibrosarcoma (6)  ·  Dermatofibrosarcoma (5)  ·  Gastrointestinal Stromal Tumors (5)  ·  Chondrosarcoma, Extraskeletal Myxoid (4)  ·  Desmoplastic Small Round Cell Tumor (4)

Broader conditions

Neoplasms by Histologic Type (47)  ·  Neoplasms, Connective and Soft Tissue (47)  ·  Neoplasms (45)  ·  Neoplasms, Connective Tissue (25)  ·  Neoplasms, Muscle Tissue (14)  ·  Neoplasms, Nerve Tissue (14)  ·  Myosarcoma (12)  ·  Neoplasms by Site (12)  ·  Neoplasms, Adipose Tissue (11)  ·  Neoplasms, Germ Cell and Embryonal (11)  ·  Neoplasms, Glandular and Epithelial (11)  ·  Neoplasms, Bone Tissue (10)  ·  Female Urogenital Diseases (9)  ·  Female Urogenital Diseases and Pregnancy Complications (9)  ·  Neoplasms, Fibrous Tissue (9)

Interventions

Doxorubicin (5)  ·  Sirolimus (5)  ·  temsirolimus (5)  ·  Bevacizumab (3)  ·  Cyclophosphamide (3)  ·  Disulfides (3)  ·  Filgrastim (3)  ·  Immunoglobulin G (3)  ·  Melphalan (3)  ·  cixutumumab (3)  ·  pazopanib (3)  ·  Biopsy (2)  ·  Fluorodeoxyglucose F18 (2)  ·  Granulocyte Colony-Stimulating Factor (2)  ·  HhAntag691 (2)

Sponsors

National Cancer Institute (NCI) (25)  ·  Northwestern University (3)  ·  Children's Oncology Group (2)  ·  City of Hope Medical Center (2)  ·  Fred Hutchinson Cancer Center (2)  ·  OHSU Knight Cancer Institute (2)  ·  AIO-Studien-gGmbH (1)  ·  Albert Einstein College of Medicine (1)  ·  Ann & Robert H Lurie Children's Hospital of Chicago (1)  ·  Fox Chase Cancer Center (1)  ·  Fuda Cancer Hospital, Guangzhou (1)  ·  Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  M.D. Anderson Cancer Center (1)  ·  National Institutes of Health Clinical Center (CC) (1)

Countries

United States (42)  ·  Canada (7)  ·  Australia (3)  ·  New Zealand (2)  ·  China (1)  ·  Germany (1)  ·  Netherlands (1)  ·  Puerto Rico (1)  ·  Switzerland (1)

Top investigators

Margaret von Mehren (2)  ·  Scott Okuno (2)  ·  Seth Pollack (2)  ·  Warren Chow (2)  ·  Anna Pawlowska, MD (1)  ·  Anusa Kalbasi, MD (1)  ·  Brenda Weigel, MD (1)  ·  Brigitte Widemann (1)  ·  Burton Eisenberg (1)  ·  Charles Keller, MD (1)  ·  Christopher W Ryan (1)  ·  David D'Adamo (1)  ·  David Walterhouse (1)  ·  H. Richard Alexander, Jr. (1)  ·  Howard Bailey (1)

Results publications

PMID 31401903, PMID 22347360, PMID 23477833, PMID 25858498, PMID 26933802, PMID 27502708, PMID 27771610, PMID 31513481, PMID 34260265, PMID 37311055, PMID 39863139, PMID 41389341, PMID 41405883

NIH funding

P30CA008748 (4), N01CM17104 (3), U01CA069856 (3), U10CA098543 (3), N01CM00038 (2), N01CM00071 (2), N01CM62206 (2), P30CA015704 (2), P30CA060553 (2), U10CA031946 (2), U10CA180821 (2), 2016 (1), K23CA175167 (1), N01CM00032 (1), N01CM00100 (1)